Tempus AI (TEM) Stock Rockets 92% as CEO Unveils Major Medicare Revenue Projections

Key Highlights

• Shares of Tempus AI surged 15% on Thursday, pushing its five-session rally to approximately 40%
• CEO Eric Lefkofsky forecasts $80M-$100M from tissue scanning diagnostics and $250M-$300M from liquid biopsy products
• The stock has rebounded 92% from its July 29 bottom of $41.55
• Analysts maintain a Moderate Buy consensus with a $66.56 average target, suggesting roughly 17% potential decline from present prices
• The data licensing division expanded 36% in the most recent quarter, featuring contracts worth over $100M with pharmaceutical giants including AstraZeneca, Merck, and GSK

Tempus AI (TEM) shares experienced a 15% surge Thursday following CEO Eric Lefkofsky’s presentation at the Morgan Stanley 24th Annual Global Healthcare Conference, where he detailed the company’s Medicare reimbursement projections. The healthcare technology firm has now rallied nearly 40% across the last five trading sessions, approaching its strongest closing price since November 2025.

Tempus AI, Inc., TEM

During his presentation, Lefkofsky outlined expectations for $80 million to $100 million in Medicare reimbursements for the company’s solid tumor tissue scanning diagnostic next year. Additionally, he projected revenues ranging from $250 million to $300 million from the liquid biopsy platform, pending regulatory approval anticipated in late 2027.

The concrete revenue projections provided investors with renewed confidence, driving significant buying activity following a challenging period after the company’s summer acquisition announcement.

The healthcare AI company announced plans in July to purchase cancer diagnostics firm Personalis for $1.5 billion, valued at $16.25 per share, with payment primarily in Tempus equity. Market participants initially reacted negatively to the stock-based transaction structure, pressuring shares downward. However, from that July 29 trough of $41.55, the stock has mounted an impressive 92% recovery.

Data Business Emerges as Critical Revenue Driver

Looking beyond diagnostic services, Lefkofsky highlighted the data licensing operation as a crucial growth catalyst. This division posted 36% growth in the latest quarter and encompasses multi-year agreements exceeding $100 million each with leading pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, GSK, Merck, and BioNTech.

Lefkofsky emphasized that Tempus maintains a comprehensive database covering 50 million patients, combined with established partnerships with healthcare systems and pharmaceutical manufacturers, providing a competitive advantage in this market segment.

The pending Personalis transaction is anticipated to bolster Tempus’ molecular residual disease capabilities while enabling the company to elevate test pricing beyond $1,000 per diagnostic over time.

For the second quarter ending July 30, Tempus delivered $382.5 million in total revenue. Diagnostics services accounted for 76% of overall sales. The company also announced $200 million in fresh licensing agreements within its data and applications division.

Analyst Perspectives on Valuation

Notwithstanding the recent rally, the Wall Street consensus price target stands at $66.56, indicating approximately 17% downside from current trading levels. The stock maintains a Moderate Buy rating, supported by 10 Buy recommendations and 7 Hold ratings issued over the past three months.

Lefkofsky dismissed concerns about excessive valuation, emphasizing that management remains concentrated on achieving 25% compound annual growth throughout the coming decade rather than near-term price fluctuations. “If you got to bet at all, every day of the week and twice on Sunday, we over-deliver,” he stated.

ARK Innovation ETF (ARKK), which counts TEM among its top three holdings alongside Tesla and SpaceX, advanced 4.3% Thursday. ARK Invest had accumulated nearly 85,000 additional TEM shares in March while reducing its Meta Platforms allocation.

TEM has appreciated more than 60% throughout the past month. The current five-day winning streak represents the stock’s most robust performance since bottoming in late July.